Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation

NCT05918042 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05918042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 21, 2023
Completion date
May 29, 2025
Enrollment
414 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer